Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Current and future cancer staging after neoadjuvant treatment for solid tumors.

Publication ,  Journal Article
Byrd, DR; Brierley, JD; Baker, TP; Sullivan, DC; Gress, DM
Published in: CA Cancer J Clin
March 2021

Until recently, cancer registries have only collected cancer clinical stage at diagnosis, before any therapy, and pathological stage after surgical resection, provided no treatment has been given before the surgery, but they have not collected stage data after neoadjuvant therapy (NAT). Because NAT is increasingly being used to treat a variety of tumors, it has become important to make the distinction between both the clinical and the pathological assessment without NAT and the assessment after NAT to avoid any misunderstanding of the significance of the clinical and pathological findings. It also is important that cancer registries collect data after NAT to assess response and effectiveness of this treatment approach on a population basis. The prefix y is used to denote stage after NAT. Currently, cancer registries of the American College of Surgeons' Commission on Cancer only partially collect y stage data, and data on the clinical response to NAT (yc or posttherapy clinical information) are not collected or recorded in a standardized fashion. In addition to NAT, nonoperative management after radiation and chemotherapy is being used with increasing frequency in rectal cancer and may be expanded to other treatment sites. Using examples from breast, rectal, and esophageal cancers, the pathological and imaging changes seen after NAT are reviewed to demonstrate appropriate staging.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

CA Cancer J Clin

DOI

EISSN

1542-4863

Publication Date

March 2021

Volume

71

Issue

2

Start / End Page

140 / 148

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Registries
  • Rectal Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Male
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Byrd, D. R., Brierley, J. D., Baker, T. P., Sullivan, D. C., & Gress, D. M. (2021). Current and future cancer staging after neoadjuvant treatment for solid tumors. CA Cancer J Clin, 71(2), 140–148. https://doi.org/10.3322/caac.21640
Byrd, David R., James D. Brierley, Thomas P. Baker, Daniel C. Sullivan, and Donna M. Gress. “Current and future cancer staging after neoadjuvant treatment for solid tumors.CA Cancer J Clin 71, no. 2 (March 2021): 140–48. https://doi.org/10.3322/caac.21640.
Byrd DR, Brierley JD, Baker TP, Sullivan DC, Gress DM. Current and future cancer staging after neoadjuvant treatment for solid tumors. CA Cancer J Clin. 2021 Mar;71(2):140–8.
Byrd, David R., et al. “Current and future cancer staging after neoadjuvant treatment for solid tumors.CA Cancer J Clin, vol. 71, no. 2, Mar. 2021, pp. 140–48. Pubmed, doi:10.3322/caac.21640.
Byrd DR, Brierley JD, Baker TP, Sullivan DC, Gress DM. Current and future cancer staging after neoadjuvant treatment for solid tumors. CA Cancer J Clin. 2021 Mar;71(2):140–148.
Journal cover image

Published In

CA Cancer J Clin

DOI

EISSN

1542-4863

Publication Date

March 2021

Volume

71

Issue

2

Start / End Page

140 / 148

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Registries
  • Rectal Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Male
  • Humans
  • Female